Medpace (NASDAQ:MEDP) Director Sells $4,414,590.45 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) Director Fred Davenport, Jr. sold 7,283 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the completion of the transaction, the director owned 3,798 shares of the company’s stock, valued at $2,302,157.70. The trade was a 65.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Medpace Stock Performance

Shares of Medpace stock traded up $8.11 on Friday, reaching $620.75. 225,439 shares of the stock were exchanged, compared to its average volume of 347,887. The firm has a market cap of $17.33 billion, a PE ratio of 36.39, a P/E/G ratio of 2.71 and a beta of 1.15. The firm’s 50 day moving average is $547.09 and its 200-day moving average is $491.80. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same period last year, the firm posted $3.10 earnings per share. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Robert W. Baird boosted their target price on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Barclays set a $600.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and increased their price objective for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $584.18.

Institutional Trading of Medpace

Hedge funds have recently made changes to their positions in the company. NewEdge Advisors LLC increased its stake in shares of Medpace by 22.1% in the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after buying an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Medpace by 3.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after acquiring an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. grew its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in Medpace in the 2nd quarter valued at approximately $296,000. Finally, M&T Bank Corp increased its position in Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after acquiring an additional 31 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.